PDK4 and lung carcinoma: Further, there has been provided in vivo evidence for a pyruvate dehydrogenase kinase 4 (PDK4)-dependent pathway activated by pioglitazone by which this PPARγ ligand increases the oxidative stress experienced by lung cancer cells, thereby ceasing their proliferation [57].